BFFTF News and Press, Biofrontera AG From 05/20/20

Biofrontera AG (BFRA) Q1 2020 Results Earnings Conference Call May 20, 2020 8:00 AM ET Company Participants Pamela Keck - Head, Investor Relations Hermann Lübbert - Chief Executive Officer Thomas Schaffer - Chief Financial Officer Conference Call Participants Bruce J...

Biofrontera Inks New Licensing Deal, Reports FY 2019 Numbers Biofrontera AG ( BFRA ) announced inking a new exclusive licensing deal with Maruho Co. Ltd. of Osaka, Japan. The deal pertains to the development and commercialization of Ameluz in East Asia and Oceania. Under the terms of the c...

Biofrontera AG (BFRA) Q4 2019 Earnings Conference Call April 21, 2020 08:00 ET Company Participants Pamela Keck - Head, Investor Relations Hermann Lübbert - Chief Executive Officer Thomas Schaffer - Chief Financial Officer Conference Call Participants Bruce Jackson - T...

Biofrontera AG ( OTC:BFFTF ): FY Net loss of €7.36M. More news on: Biofrontera AG, Biofrontera AG, Earnings news and commentary, , Read more ...

Biofrontera AG ( OTC:BFFTF ): 1H net income of €9M More news on: Biofrontera AG, Earnings news and commentary, Read more ...

Nanoemulsion Starting out as a scientist in the investing world, I was always fascinated by the behind hidden technology. Especially for biotech, understanding the scientific platform is something crucial to succeed. Nanotechnology is, in general, the process of creating small size cryst...

Editor's note: Seeking Alpha is proud to welcome End On Equity as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Essential. Click here to find out more » Biofrontera ( BFR...

Biofrontera ( BFRA ; BFFTF ) has been gradually shifting from a biotech company into a focused pharmaceutical company with specialization in dermatology. The central turning point was the European approval of the self-developed medication Ameluz for the photodynamic therapy of actinic keratos...